Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
Campbell
K R
KR
Duke Clinical Research Institute, P.O. Box 17969, Durham, NC 27715, USA.
Mahaffey
K W
KW
Lewis
B E
BE
Weitz
J I
JI
Berkowitz
S D
SD
Ohman
E M
EM
Califf
R M
RM
D000787:Angina Pectoris / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods; D000925:Anticoagulants / Q000009:adverse effects*; D000991:Antithrombins / Q000627:therapeutic use*; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control; D006493:Heparin / Q000009:adverse effects*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012449:Safety; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy; D016896:Treatment Outcome
D000925:Anticoagulants; D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin